Since TNBC is highly immunogenic with higher PD-L1 expression and immune-infiltration compared with luminal and HER2-enriched breast cancers, immunotherapy has been represented as a promising treatment strategy for TNBC [35,36]. The gene discussed is ERBB2; the disease is breast cancer.